Understanding GLP-1s and their dynamic marketplace and workplace trends
With the availability of newer treatment options for weight management – glucagon-like peptide 1 (GLP-1) medications – metabolic health is in the news, shining a light for the public on the impact of weight on overall health.
When evaluating patient well-being, physicians are increasingly reviewing metabolic health as an indicator of future health risk. Metabolic health factors – including a patient’s cholesterol profile, waist circumference, blood pressure and blood glucose – are interconnected. Obesity is a multi-faceted medical condition that typically manifests as a result of several factors, including genetic makeup, use of certain medications, lack of physical activity, excessive calorie consumption and sleep patterns.1 There are over 200 conditions associated with obesity, including cardiovascular disease, diabetes, fatty liver disease and cancer.2 It is well documented that even a 10% reduction in body weight has health benefits.